Australia Intravenous Immunoglobulin Market Size & Outlook

The intravenous immunoglobulin market in Australia is expected to reach a projected revenue of US$ 519.0 million by 2030. A compound annual growth rate of 8.3% is expected of Australia intravenous immunoglobulin market from 2025 to 2030.
Revenue, 2024 (US$M)
$320.1
Forecast, 2030 (US$M)
$519.0
CAGR, 2025 - 2030
8.3%
Report Coverage
Australia

Australia intravenous immunoglobulin market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Australia intravenous immunoglobulin market, 2018-2030 (US$M)

Australia intravenous immunoglobulin market highlights

  • The Australia intravenous immunoglobulin market generated a revenue of USD 320.1 million in 2024 and is expected to reach USD 519.0 million by 2030.
  • The Australia market is expected to grow at a CAGR of 8.3% from 2025 to 2030.
  • In terms of segment, hypogammaglobulinemia was the largest revenue generating application in 2024.
  • Kawasaki Disease is the most lucrative application segment registering the fastest growth during the forecast period.

Intravenous immunoglobulin market data book summary

Market revenue in 2024USD 320.1 million
Market revenue in 2030USD 519.0 million
Growth rate8.3% (CAGR from 2025 to 2030)
Largest segmentHypogammaglobulinemia
Fastest growing segmentKawasaki Disease
Historical data2018 - 2023
Base year2024
Forecast period2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationImmunodeficiency diseases, CIDP, Hypogammaglobulinemia, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome
Key market players worldwideBiotest AG ADR, Baxter International Inc, Grifols SA Ordinary Shares - Class A, CSL Ltd, Octapharma AG, LFB (Laboratoire Français du Fractionnement et des Biotechnologies), Taibang Biological Group, Kedrion Biopharma

Other key industry trends

  • In terms of revenue, Australia accounted for 2.3% of the global intravenous immunoglobulin market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, Japan intravenous immunoglobulin market is projected to lead the regional market in terms of revenue in 2030.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,078.8 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Intravenous Immunoglobulin Market Companies

Name Profile # Employees HQ Website

Australia intravenous immunoglobulin market size, by application, 2018-2030 (US$M)

Australia Intravenous Immunoglobulin Market Outlook Share, 2024 & 2030 (US$M)

Australia intravenous immunoglobulin market size, by application, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more